2024
Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort.
Erlandson K, Geng L, Selvaggi C, Thaweethai T, Chen P, Erdmann N, Goldman J, Henrich T, Hornig M, Karlson E, Katz S, Kim C, Cribbs S, Laiyemo A, Letts R, Lin J, Marathe J, Parthasarathy S, Patterson T, Taylor B, Duffy E, Haack M, Julg B, Maranga G, Hernandez C, Singer N, Han J, Pemu P, Brim H, Ashktorab H, Charney A, Wisnivesky J, Lin J, Chu H, Go M, Singh U, Levitan E, Goepfert P, Nikolich J, Hsu H, Peluso M, Kelly J, Okumura M, Flaherman V, Quigley J, Krishnan J, Scholand M, Hess R, Metz T, Costantine M, Rouse D, Taylor B, Goldberg M, Marshall G, Wood J, Warren D, Horwitz L, Foulkes A, McComsey G. Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort. Annals Of Internal Medicine 2024, 177: 1209-1221. PMID: 39133923, PMCID: PMC11408082, DOI: 10.7326/m24-0737.Peer-Reviewed Original ResearchPostacute sequelae of SARS-CoV-2 infectionSARS-CoV-2 infectionLaboratory markersSARS-CoV-2Laboratory valuesUrinary albumin-creatinine ratioClinical laboratory markersStandard clinical laboratory testsAlbumin-creatinine ratioClinical laboratory valuesHemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>Clinically useful biomarkersClinical laboratory testsClinical laboratory measurementsPropensity score adjustmentSequelae of SARS-CoV-2 infectionPreexisting diabetesIndex dateMeasured 6 monthsClinical significanceNational Institutes of HealthStudy visitsEnrollment siteRisk factorsClinical biomarkers
2018
Usefulness of a Simple Algorithm to Identify Hypertensive Patients Who Benefit from Intensive Blood Pressure Lowering
Wang S, Khera R, Das SR, Vigen R, Wang T, Luo X, Lu R, Zhan X, Xiao G, Vongpatanasin W, Xie Y. Usefulness of a Simple Algorithm to Identify Hypertensive Patients Who Benefit from Intensive Blood Pressure Lowering. The American Journal Of Cardiology 2018, 122: 248-254. PMID: 29880288, DOI: 10.1016/j.amjcard.2018.03.361.Peer-Reviewed Original ResearchConceptsSystolic Blood Pressure Intervention TrialIntensive BP loweringUrinary albumin-creatinine ratioFavorable risk-benefit profileAlbumin-creatinine ratioBP loweringRisk-benefit profileHypertensive patientsBlood pressureMajor adverse cardiovascular event ratesAdverse cardiovascular event ratesIntensive blood pressure loweringMajor adverse cardiovascular eventsRemaining low-risk patientsSimple risk prediction modelIntensive blood pressureStandard BP loweringAdverse cardiovascular eventsBlood pressure loweringSerious adverse eventsCardiovascular event ratesLarge randomized trialsLow-risk patientsSubset of patientsCardiovascular disease risk
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply